ライフサイエンスコーパス: thromboembolic event

1 ricular arrhythmias, 5 cardiac deaths, and 5 thromboembolic events).

2 hemopericardium, and 5 patients (0.7%) had a thromboembolic event.

3 to death, first major haemorrhage, and first thromboembolic event.

4 One patient (1.6%) had a thromboembolic event.

5 ardial infarction, stroke, heart failure, or thromboembolic event.

6 deaths, the probable cause of death was the thromboembolic event.

7 c therapy was reduced (p < 0.06) without any thromboembolic event.

8 Thirteen patients (13%) had a thromboembolic event.

9 lder age, smoking, node negativity, or prior thromboembolic event.

10 ascular event, and 14,550 had a first venous thromboembolic event.

11 ntation, new heart failure, stroke, or other thromboembolic event.

12 long-term survival and very low incidence of thromboembolic events.

13 and fractures and increased the incidence of thromboembolic events.

14 with respect to the incidence of bleeding or thromboembolic events.

15 rophylaxis do not have an increased risk for thromboembolic events.

16 al relevance in prophylaxis and treatment of thromboembolic events.

17 f statins (or higher dose statins) on venous thromboembolic events.

18 m 0.68 to 0.72, P<0.0001, for a composite of thromboembolic events.

19 at high risk for arrhythmic sudden death and thromboembolic events.

20 tins substantially reduce the risk of venous thromboembolic events.

21 for translation due to its association with thromboembolic events.

22 ves during pregnancy is essential to prevent thromboembolic events.

23 carotid artery stenting reduces the rate of thromboembolic events.

24 of lasofoxifene increased the risk of venous thromboembolic events.

25 , and stroke but an increased risk of venous thromboembolic events.

26 8 patients with AF, we observed 676 incident thromboembolic events.

27 proportional reporting of syncope and venous thromboembolic events.

28 dverse event of grade 3 or worse, especially thromboembolic events.

29 discussed as are recommendations to prevent thromboembolic events.

30 re found, of which 168 reports described 185 thromboembolic events.

31 infections may also contribute to the acute thromboembolic events.

32 tion, while 4 of these 18 (22%) patients had thromboembolic events.

33 rom one that is at high risk for rupture and thromboembolic events.

34 thy have multiple factors that predispose to thromboembolic events.

35 Four patients developed thromboembolic events.

36 plasma homocysteine (tHcy) and high risk of thromboembolic events.

37 c atrial flutter are at an increased risk of thromboembolic events.

38 to initiate and exacerbate atherogenesis and thromboembolic events.

39 cognized risk factor for atherosclerosis and thromboembolic events.

40 s, non-O blood groups explain >30% of venous thromboembolic events.

41 higher incidence of both venous and arterial thromboembolic events.

42 ted, including all-cause mortality and fatal thromboembolic events.

43 associated complications of arrhythmias and thromboembolic events.

44 bleeding risk without a favorable effect on thromboembolic events.

45 ular atrial fibrillation is a major cause of thromboembolic events.

46 pathogenesis of atherosclerosis, leading to thromboembolic events.

47 ), thresholds were stable, and there were no thromboembolic events.

48 lation has been associated with some risk of thromboembolic events.

49 2.03, hemolysis 0.61, device infection 0.16, thromboembolic event 0.61, pump thrombus 0.61, and pump

50 ted therapy showed significant reductions in thromboembolic events (0.27, 0.12-0.59) and death (0.37,

51 anticoagulated patients experienced nonfatal thromboembolic events (1.1%/year), whereas 13 with apica

52 arrhoea (nine [7%] vs nine [7%]), and venous thromboembolic events (11 [8%] vs six [4%]).

53 ; adjusted IRR, 2.93; 95% CI, 1.54-5.55) for thromboembolic events; 11.86 (95% CI, 7.81-18.01) vs 5.3

54 Thromboembolic events (12.5%), hypertension (12.5%), hyp

55 d superficial surgical-site infections, 2040 thromboembolic events, 1338 myocardial infarctions, and

56 years; 30 of the patients (20%) developed 32 thromboembolic events (15 arterial and 17 venous events)

57 readmissions, followed by cardiovascular or thromboembolic events (18%).

58 [2%] patients), and grade 3 or higher venous thromboembolic events (23 [8%] vs 11 [4%] patients) than

59 There were 39 thromboembolic events (3.7% strokes [n=29] and 1.3% tran

60 , were associated with an increase in venous thromboembolic events (3.8 and 2.9 cases vs. 1.4 cases p

61 idence interval [CI]: 0.5% to 1.0%) definite thromboembolic events (31 strokes) within 30 days (media

62 than in the placebo group experienced venous thromboembolic events (34 vs 12; RH, 2.89; 95% CI, 1.50-

63 Among 11,526 patients, 397 incident thromboembolic events (372 ischemic strokes, 25 peripher

64 had little impact on the findings for venous thromboembolic events (431 [0.9%] versus 461 [1.0%], OR

65 not significantly reduce the risk of venous thromboembolic events (465 [0.9%] statin versus 521 [1.0

66 rotocol-defined withdrawal criteria (11 [4%] thromboembolic events, 5 [2%] exceeding liver enzyme thr

67 Rates of thromboembolic events (6%) and hepatobiliary adverse eve

68 g muscles and/or joints (8/11), vascular and thromboembolic events (6/11), that is, deep vein thrombo

69 r complications (8.6% vs 0.1%; P=0.037), and thromboembolic events (8.6% vs 6.0%; P=0.037) were highe

70 requirements without increasing the risk of thromboembolic events across a wide variety of liver tra

71 patients with atrial flutter are at risk for thromboembolic events after cardioversion, although this

72 the incidence of LAA thrombus formation and thromboembolic events after LAAI.

73 site endpoint of HIT-specific complications (thromboembolic events, amputation, skin necrosis) occurr

74 Three thromboembolic events and 1 major bleeding event occurre

75 ants and antiplatelet medications to prevent thromboembolic events and access thrombosis in dialysis

76 The safety outcomes were thromboembolic events and all-cause mortality within 30

77 vasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistical

78 , patients with paroxysmal AF suffered fewer thromboembolic events and deaths compared with those wit

79 The treatment did increase the rate of thromboembolic events and gallbladder disease.

80 toring and self-adjusting therapy have fewer thromboembolic events and lower mortality than those who

81 an increased incidence of cardiovascular and thromboembolic events and more deaths during the initial

82 There were no thromboembolic events and no animals succumbed to their

83 optical density; had a higher prevalence of thromboembolic events and reached platelet count nadir l

84 Data regarding the risk of thromboembolic events and stroke after LAAI are sparse.

85 ver, 19 (46%) had arrhythmias, 5 (12%) had a thromboembolic event, and 1 (2%) developed protein-losin

86 lower risk of coronary heart disease, venous thromboembolic event, and cerebrovascular disease than i

87 ents (AEs), such as intracranial hemorrhage, thromboembolic event, and progressive aortic insufficien

88 osis and the incidence of malignancy, venous thromboembolic events, and cardiovascular disease.

89 including severe heart failure, arrhythmias, thromboembolic events, and death, the majority of women

90 afety end point was a composite of bleeding, thromboembolic events, and death.

91 ile (adverse events, serious adverse events, thromboembolic events, and deaths) was similar between g

92 as not apparent for emergencies unrelated to thromboembolic events, and did not occur in a control gr

93 nd estrogen-progestin increased the risk for thromboembolic events, and etidronate increased the risk

94 reduces mammographic sensitivity, increases thromboembolic events, and increases endometrial cancer

95 Gastrointestinal side effects, hot flashes, thromboembolic events, and infections vary among drugs.

96 or pericardial effusions, peripheral edema, thromboembolic events, and intermittent hypotension.

97 h) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular even

98 were no acute neurological complications, no thromboembolic events, and no bleeding complications.

99 ment-related deaths, second primary cancers, thromboembolic events, and peripheral neuropathy.

100 heart failure, hospitalization, arrhythmia, thromboembolic events, and reintervention).

101 eadache; aseptic meningitis, skin reactions, thromboembolic events, and renal tubular necrosis occurr

102 lower rates of cardiovascular events, venous thromboembolic events, and total mortality.

103 rse events; raloxifene and estrogen increase thromboembolic events; and estrogen causes additional ad

104 ents with lupus anticoagulants who sustain a thromboembolic event are controversial.

105 ma samples obtained from patients with prior thromboembolic events are denser and less susceptible to

106 Prophylaxis against and treatment of thromboembolic events are necessary and should consider

107 A substantial number of patients at risk for thromboembolic events are not anticoagulated, and furthe

108 sk factors associated with these symptomatic thromboembolic events are not well defined.

109 Thromboembolic events are reported in approximately one

110 Thromboembolic events are thought to be rare after cardi

111 The proportion of patients with arterial thromboembolic events as defined by the Antiplatelet Tri

112 device were more likely to have had multiple thromboembolic events at baseline.

113 Patients with AF also may have thromboembolic events at higher INR levels.

114 ing or thromboembolism, patients with AF had thromboembolic events at higher international normalized

115 Arterial thromboembolic events (ATE) have been described with the

116 vents, but focused on the subset of arterial thromboembolic events (ATEs), comprising CV death, myoca

117 reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimmune disorders, and Guillai

118 essment must address each patient's risk for thromboembolic events balanced against the risk for peri

119 reful case-by-case analysis of the risks for thromboembolic events balanced by the risks for anticoag

120 nce in the prevalence of thrombocytopenia or thromboembolic events between the antibody-positive and-

121 There were no differences in thromboembolic events between the groups (22 [6.0%] vs 3

122 im of this study was to compare the risk for thromboembolic events, bleeding, and mortality associate

123 arboplatin, as were hypertension, infection, thromboembolic events, bleeding, and postoperative compl

124 hospitalization, but no increase in risks of thromboembolic events, bleeding-related hospitalization,

125 Harms include CHD, stroke, thromboembolic events, breast cancer with 5 or more year

126 d thrombin activity underlies obesity-linked thromboembolic events, but the mechanistic links between

127 1.60 [CI, 1.15 to 2.23]; 2 trials) increase thromboembolic events by 4 to 7 per 1000 women per year;

128 ges associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or

129 ble electronic devices and increased risk of thromboembolic events, clinical intervention for device-

130 ll and major bleeding and at similar risk of thromboembolic events compared to nonbridged patients.

131 se statin therapy reduced the risk of venous thromboembolic events compared with standard dose statin

132 eriprocedural risk of complications, such as thromboembolic events, compared to warfarin discontinuat

133 CTDa was associated with higher rates of thromboembolic events, constipation, infection, and neur

134 The major adverse events were thromboembolic events, corticosteroid-related morbidity,

135 Outcomes analysed were: major haemorrhage, thromboembolic events, death, tests in range, minor haem

136 nced grade 3 to 4 toxicity, and 10 (20%) had thromboembolic events (deep venous thrombosis or pulmona

137 e, myocardial infarction, and other arterial thromboembolic events defined by the Antiplatelet Triali

138 utropenia grade 3 or 4: 21% vs 5%, P < .001; thromboembolic events despite aspirin prophylaxis: 23.5%

139 ted for unpublished information about venous thromboembolic events during follow-up.

140 diagnostic strategy, defined as adjudicated thromboembolic events during the 3-month follow-up perio

141 o evaluate the previously reported excess of thromboembolic events during the 30 days after the end o

142 The incidence of thromboembolic events during therapy was 9%.

143 stroke and non-central nervous system (CNS) thromboembolic events early after discontinuation of riv

144 Rates of freedom from thromboembolic events, endocarditis and anticoagulant-re

145 postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts

146 center, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibril

147 re to describe the incidence and spectrum of thromboembolic events experienced by patients with moder

148 Patients were observed for thromboembolic events for 3 months.

149 There was a higher incidence of thromboembolic events for the transfusion threshold of 1

150 here show that systemic hypoxia accelerates thromboembolic events, functionally stimulated by the ac

151 for fractures but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary

152 For patients at high risk for thromboembolic events, guidelines recommend bridging the

153 ll as 2-year risk of death, hospitalization, thromboembolic events, heart failure (HF), and AF progre

154 Outcome was a composite of thromboembolic events, heart failure hospitalizations, v

155 bioprostheses have an elevated early risk of thromboembolic events; however, the risks and benefits o

156 l events; HR 3.7, 95% CI 1.3-10.3 for venous thromboembolic events; HR 1.5, 95% CI 0.7-3.2 for cerebr

157 There was one grade 3 thromboembolic event in the combination arm and one inte

158 nths in patients experiencing a first venous thromboembolic event in the setting of major, transient

159 There was no difference in the risk of thromboembolic events in 8 studies comparing bridged and

160 ed with a transient increased risk of venous thromboembolic events in a community setting.

161 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

162 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

163 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

164 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

165 d Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

166 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

167 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]

168 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARIS

169 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who r

170 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

171 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

172 nomenon in the etiology of postcardioversion thromboembolic events in atrial fibrillation.

173 systematically identified symptomatic venous thromboembolic events in both trials.

174 re clinical use is uncertain due to reported thromboembolic events in clinical trials.

175 The risk of thromboembolic events in heart failure patients is estim

176 a-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.

177 Consequently, the prevention of thromboembolic events in LA positives might improve surv

178 b and bevacizumab may contribute to systemic thromboembolic events in patients aged 65 years or older

179 Semuloparin reduces the incidence of thromboembolic events in patients receiving chemotherapy

180 ar-weight heparin aims to reduce the risk of thromboembolic events in patients receiving long-term vi

181 egarding the effectiveness and occurrence of thromboembolic events in patients treated with prothromb

182 e and efficacious in preventing bleeding and thromboembolic events in patients undergoing AF ablation

183 ent are largely the same as those predicting thromboembolic events in patients with atrial fibrillati

184 Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillati

185 E constituted 11.5% of clinically recognized thromboembolic events in patients with atrial fibrillati

186 erapy is the standard therapy for preventing thromboembolic events in patients with atrial fibrillati

187 ailable published data regarding the risk of thromboembolic events in patients with dilated cardiomyo

188 The annual incidence of thromboembolic events in patients with heart failure is

189 Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, ir

190 rophylactic anticoagulation and treatment of thromboembolic events in patients with hepatic insuffici

191 of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atria

192 The incidence of thromboembolic events in the 48 hours after ablation was

193 30) and trend toward more cardiovascular and thromboembolic events in the NCRT group (P=0.069).

194 Evaluating possible thromboembolic events in the non-human primate has tradi

195 e, and inexpensive method to assess possible thromboembolic events in the non-human primate.

196 We sought to evaluate the risk of thromboembolic events in the presence of chronic atrial

197 We reported a significant reduction in thromboembolic events in the self-monitoring group (haza

198 Platelet reactivity predisposes to thromboembolic events in the setting of atherosclerotic

199 However, reports of the incidence of thromboembolic events in this population vary widely.

200 ade 5 adverse events, including two arterial thromboembolic events, in the bevacizumab group, and 14

201 Thromboembolic events include strokes, pulmonary emboli

202 with heart failure are at increased risk for thromboembolic events, including stroke.

203 e modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutr

204 Ligation of the LAA to prevent future thromboembolic events is commonly performed during mitra

205 on and sinus rhythm, the annual incidence of thromboembolic events is low.

206 agulable state were included if the observed thromboembolic event met one or more of four criteria fo

207 levant safety end points, including arterial thromboembolic events, MI, stroke or transient ischemic

208 es, but tamoxifen increased the incidence of thromboembolic events more than raloxifene by 4 cases in

209 isks of both invasive endometrial cancer and thromboembolic events must be balanced in older women.

210 Severe toxicities included thromboembolic events (n = 3) and allergic reactions (n

211 ositis (none vs four [10%] vs one [3%]), and thromboembolic event (none vs three [8%] vs two [5%]).

212 g the first cycle of therapy, and one venous thromboembolic event occurred during the study.

213 A single thromboembolic event occurred in each of the dabigatran

214 Five thromboembolic events occurred (one PC-SPES, four DES).

215 In the remaining six patients (6%), thromboembolic events occurred during a rhythm of atrial

216 Grade 3 to 4 thromboembolic events occurred in 25% of patients.

217 Thromboembolic events occurred in 4 subjects receiving d

218 Thromboembolic events occurred in 73 of 7118 bridged pat

219 Thromboembolic events occurred in one patient receiving

220 ring days 1-720, ten (1.2% per patient year) thromboembolic events occurred in the Fiix-PT group vers

221 Arterial thromboembolic events occurred in three patients (6.8%).

222 Thromboembolic events occurred less often in the raloxif

223 Three thromboembolic events occurred within 3 days (one in the

224 Reported thromboembolic events occurring in patients administered

225 study was terminated prematurely because of thromboembolic events occurring in patients in this and

226 d estimates showed significant reductions in thromboembolic events (odds ratio 0.45, 95% CI 0.30-0.68

227 and nonsignificant lower risk of stroke and thromboembolic events (odds ratio =0.61, 95% confidence

228 There was no difference in thromboembolic events (odds ratio, 0.30; 95% CI, 0.04-2.

229 mly assigned patients with an annual risk of thromboembolic events of 5% or more to continued warfari

230 ertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%),

231 Thromboembolic events on dabigatran led to early termina

232 unknown cause (one patient), and a possible thromboembolic event (one patient).

233 s in the combination arm experienced serious thromboembolic events (one death).

234 rom study for drug-associated toxicity (five thromboembolic events, one bowel perforation).

235 cular rate control was begun, had a clinical thromboembolic event: One had a stroke, 1 had a transien

236 e on treatment efficacy, the impact of fatal thromboembolic events, optimal anticoagulation therapy,

237 There was no difference in rates of thromboembolic events or other complications between the

238 d up to the time of intracranial hemorrhage, thromboembolic event, or progressive aortic insufficienc

239 zations (early or late), clinical hemolysis, thromboembolic events, or hemodynamic deterioration occu

240 e incidence of diarrhea, hand-foot syndrome, thromboembolic events, or serious bleeding episodes betw

241 e aortic insufficiency (P=0.078) but not for thromboembolic event (P=0.638).

242 ejection fraction and gender on the risk of thromboembolic events (p = 0.04).

243 erebrovascular disease (P<0.001), and venous thromboembolic events (P<0.001) than those reporting doi

244 ase duration; hemoglobin level; frequency of thromboembolic events, palpable splenomegaly, and splene

245 The absolute rate increase was 1.5 venous thromboembolic events per 10 000 women in 1 year.

246 ere were 0.75 major bleeding events and 0.28 thromboembolic events per patient year of follow-up.

247 (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological e

248 Thromboembolic event rates differed markedly in non-anti

249 We explored the variation in thromboembolic event rates in a non-anticoagulated AF po

250 d 13 in the placebo group experienced venous thromboembolic events (relative hazard, 2.7 [95% CI, 1.4

251 e frequent clinical complications, including thromboembolic events, seizures, fluctuations in neurolo

252 paroid (where available) reduces the risk of thromboembolic events, some of which may be life-threate

253 Emergency visits for thromboembolic events spanning 1-4 years before treatmen

254 had lower risk-adjusted all-cause mortality, thromboembolic events, subsequent depression, alcoholism

255 ial fibrillation (AF) have increased risk of thromboembolic events such as stroke and myocardial infa

256 s finding the optimal equilibrium to prevent thromboembolic events, such as stent thrombosis and thro

257 No thrombotic or thromboembolic events, systemic allergic reactions (incl

258 primary breast cancer but increase risk for thromboembolic events (tamoxifen, raloxifene), endometri

259 Thrombotic/thromboembolic events (TEE) have been reported with plas

260 termine the incidence of venous and arterial thromboembolic events (TEEs) in patients treated with ci

261 ied a boxed safety warning about the risk of thromboembolic events (TEEs), with TEEs reported in 0.5%

262 e predictive value of stroke risk scores for thromboembolic events (TEs) after catheter ablation of a

263 s with atrial fibrillation (AF), the risk of thromboembolic events (TEs) is variable and is influence

264 malignancy are at increased risk for venous thromboembolic events (TEs).

265 nd atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure a

266 ith atrial flutter had a higher incidence of thromboembolic events than the sample control patients a

267 We identified 685 validated thromboembolic events that occurred during 32,721 person

268 t to be associated with a negligible risk of thromboembolic events; therefore, anticoagulation is com

269 i-Platelet Trialists' Collaboration arterial thromboembolic events through W96.

270 Venous thromboembolic events (VTE) are potentially preventable

271 is are associated with lower rates of venous thromboembolic events (VTE), major bleeding, and superfi

272 ver, seven of 21 patients experienced venous thromboembolic events (VTEs) during TAC-101 treatment.

273 However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemot

274 ality, stroke, myocardial infarction, venous thromboembolic events (VTEs), and hypertension.

275 ty, accounts for the highest rates of venous thromboembolic events (VTEs).

276 for cardiovascular safety, only one further thromboembolic event was reported (fatal pulmonary embol

277 The 3-month rate of subsequent venous thromboembolic events was 1.4% (95% CI, 1.1% to 1.8%), a

278 The overall annual incidence of thromboembolic events was 2.4% in women and 1.8% in men.

279 For pulmonary embolism, history of previous thromboembolic events was identified as the only risk fa

280 proportional reporting of syncope and venous thromboembolic events was noted with data mining methods

281 sient ischemic attack (TIA), or a peripheral thromboembolic event were randomly assigned to undergo c

282 Rates of venous thromboembolic events were also lower among statin users

283 Patient characteristics, warfarin use, and thromboembolic events were ascertained from clinical dat

284 Sudden, unexpected thromboembolic events were characterized as a vascular s

285 f hospitalizations for bleeding and arterial thromboembolic events were estimated in an intent-to-tre

286 l events, cerebrovascular events, and venous thromboembolic events were estimated to be 19.6%, 21.6%,

287 Venous thromboembolic events were increased in all tamoxifen st

288 events and 33 and 58 and 12 and 28 arterial thromboembolic events were observed during follow-up, re

289 No thromboembolic events were observed during the study.

290 ng, peripheral neuropathy, hearing loss, and thromboembolic events were relatively common.

291 Arterial thromboembolic events were reported in 5.6% of the patie

292 Thromboembolic events were significantly increased with

293 Thromboembolic events were the likely cause of various c

294 This effect increases the risk of venous thromboembolic events, which is reflected in the results

295 diagnosis and seven of those had documented thromboembolic event while on extracorporeal membrane ox

296 hagic and ischemic stroke, or between venous thromboembolic events with or without pulmonary embolism

297 Prevention of thromboembolic events with oral anticoagulants in nephro

298 sociated with significantly fewer deaths and thromboembolic events, without increased risk for a seri